Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
|ClinicalTrials.gov Identifier: NCT03060720|
Recruitment Status : Active, not recruiting
First Posted : February 23, 2017
Last Update Posted : March 6, 2020
|Condition or disease|
This research is being done to identify which pancreatic cancer patients should undergo genetic evaluation. A patient's personal and family history of cancer is the information typically used to make this decision, but there are currently no accurate, evidence-based guidelines that exist to help doctors use this information to make a decision.
The investigators hope that by testing all new pancreatic cancer patients, they can determine which clinical factors predict for genetic mutations in order to create a risk assessment tool.
The investigators want to determine which patients with pancreatic cancer will benefit from genetic testing. To do so, the investigators will offer all patients with pancreatic cancer in the Dana-Farber Gastrointestinal Oncology clinic referral for genetic evaluation. At the Cancer Genetics and Prevention clinic appointment, the provider will review the patient's personal and familial history of cancer and offer genetic testing.
|Study Type :||Observational|
|Actual Enrollment :||271 participants|
|Official Title:||Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy|
|Actual Study Start Date :||February 24, 2017|
|Actual Primary Completion Date :||April 7, 2019|
|Estimated Study Completion Date :||February 2022|
- We will measure clinical factors (e.g. # of PDAC patients with a personal history of x,y,z; # of PDAC patients with a family history of x,y,z; # PDAC patients with a germline mutation in x,y,z) so as to develop a risk assessment tool [ Time Frame: Up to 5 years ]
- Evaluate Patient Experience With Genetic Testing [ Time Frame: up to 5 years ]
- Summarize patient satisfaction with Genetic counseling [ Time Frame: up to 5 years ]
- Number of patients who disclose genetic testing results to relatives [ Time Frame: up to 5 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03060720
|United States, Massachusetts|
|Dana Farber Cancer Institute|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Matthew B Yurgelun, MD||Dana-Farber Cancer Institute|